



Government of Pakistan
Public Procurement Regulatory Authority
(Monitoring & Evaluation Wing)



No: 11(160)/M&E/PPRA/2018/222

Islamabad, June 02, 2021

Subject: **PROCUREMENT OF DRUGS WHICH ARE REGISTERED AND APPROVED BY DRAP**

I am directed to refer to Transparency International Pakistan's letter No. TL21/04/22/1A dated April 22, 2021 addressed to this Authority, wherein Transparency International Pakistan has made certain observations regarding adoption of Quality Based Selection method for the procurement of pharmaceutical goods by the procuring agencies.

2. It is apprised that, the Authority is in process of developing Standard Bidding Documents (SBDs) for the procurement of pharmaceutical goods for which feedback from the Drug Regulatory Authority of Pakistan (DRAP) and other stakeholders including relevant experts would be taken into account. Meanwhile, all the directions issued by DRAP including the one issued vide letter dated 16th April 2021 be complied with subject to the fulfillment of guidelines on the quality (of the products) issued by the same Authority. However, it may be ensured that the whole process is not in conflict with any provision of the Public Procurement Regulatory Framework.

3. Furthermore, after procurement, random testing of drugs should be conducted through designated drug testing laboratories to ensure that the samples are in accordance with the required specifications and meet all requisite quality standards as approved by DRAP.

(Engr. Muhammad Saleh Izhar)
Deputy Director (M&E)

All Federal Secretaries

CC:

- i. **Justice (R) Nasira Iqbal (SI)**, Vice Chair, Transparency International Pakistan, Plot 72-F/2, 1st Floor, 9th Street, Jami Commercial, Phase VII, Defence Housing Authority, Karachi.
- ii. **Director (MIS) PPRA**, with request to upload the same on the Authority's Website.